

Claim 4, line 2, please delete "antigen" and substitute --immunogen-- therefore.

Claim 5, line 2, please delete "antigen" and substitute --immunogen-- therefore.

Claim 6, line 2, please delete "antigen" and substitute --immunogen-- therefore.

Claim 6, line 3, please delete "antigen" and substitute --immunogen-- therefore.

Claim 6, line 3, please delete "AlpA" and substitute --adherence-associated lipoprotein A (AlpA)-- therefore.

Claim 6, line 3, please delete "AlpB" and substitute --adherence-associated lipoprotein B (AlpB)-- therefore.

Claim 7, line 3, please delete "antigen" and substitute --immunogen-- therefore.

Claim 8, line 3, please delete "antigen" and substitute --immunogen-- therefore.

NE more than 5 words insertion R121

Claim 11. Pharmaceutical composition comprising as an active agent a recombinant attenuated ^{LAB}pathogen according to claim 1, [optionally] together with a pharmaceutically acceptable diluent, carrier or adjuvant [diluent, carriers and adjuvants].

C 3
See Entry
Claim 13. A method for the preparation of a living vaccine comprising [formulating an attenuated pathogen according to claim 1]-^{LA-13} providing the attenuated pathogen of claim 1 and formulating the attenuated pathogen in a pharmaceutically effective amount for inducing protective immunity with pharmaceutically acceptable diluents, carriers [and/or] or adjuvants.

Claim 14, line 5, please delete "antigen" and substitute --immunogen-- therefore.

Claim 15, line 3, please delete "antigen" and substitute --immunogen-- therefore.

Claim 16, line 1, please delete "antigens" and substitute --immunogens-- therefore.

Please add new claims 17-21 as follows.

Claim 17. Composition according to claim 11, which is a living vaccine, wherein said composition is in a form suitable for administration to a mucosal surface.

C 4
Claim 18. Composition according to claim 11, which is a living vaccine, wherein said composition is in a form suitable for administration via the parenteral route.

Sub Entry
Claim 19. A method of treating an infection by *Helicobacter pylori*, comprising administering to a patient in need thereof a composition comprising the attenuated pathogen of claim 1 in a pharmaceutically effective amount for inducing protective immunity.

Sub (3)
Claim 20. A method of preventing an infection by *Helicobacter pylori*, comprising administering to a patient a composition comprising the attenuated pathogen of claim 1 in a pharmaceutically effective amount for inducing protective immunity.

C4 cont OK
Claim 21. The method according to claim 19 or 20, wherein the composition is administered as a single dose.

In the specification:

C5
Page 1, line 3, please insert --This application is a 371 application of PCT/EP97/04744, which was filed January 9, 1997.--

/
Page 10, line 28, please insert --SEQ ID NO.: 7-- after "sequence".

/
Page 13, line 11, please insert --SEQ ID NO.: 8-- before "and".

/
Page 13, line 12, please insert --SEQ ID NO.: 9-- before "for".

In the abstract:

Please insert the abstract of the disclosure attached hereto as a separate sheet.